CLX · Clorox Co /De/ - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $7.10B | $7.09B | $7.39B | $7.11B | $7.34B | $6.72B |
| Cost of Revenue | $3.89B | $4.04B | $4.48B | $4.56B | $4.14B | $3.66B |
| Gross Profit | $3.21B | $3.05B | $2.91B | $2.54B | $3.20B | $3.06B |
| R&D | $121.00M | $126.00M | $138.00M | $132.00M | $149.00M | $145.00M |
| SG&A | $1.12B | $1.17B | $1.18B | $954.00M | $1.00B | $969.00M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $219.00M | $235.00M | $236.00M | $224.00M | $211.00M | $180.00M |
| Operating Income | $1.08B | $398.00M | $238.00M | $607.00M | $900.00M | $1.19B |
| Interest Expense | $88.00M | $90.00M | $90.00M | $106.00M | $99.00M | $99.00M |
| Income Tax | $254.00M | $106.00M | $77.00M | $136.00M | $181.00M | $246.00M |
| Net Income | $810.00M | $280.00M | $149.00M | $462.00M | $710.00M | $939.00M |
| EPS - Basic | $6.56 | $2.26 | $1.21 | $3.75 | $5.66 | $7.46 |
| EPS - Diluted | $6.52 | $2.25 | $1.20 | $3.73 | $5.58 | $7.36 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $167.00M | $202.00M | $367.00M | $183.00M | $319.00M | $871.00M |
| Accounts Receivable | $821.00M | $695.00M | $688.00M | $681.00M | $604.00M | $648.00M |
| Inventory | $523.00M | $637.00M | $696.00M | $755.00M | $752.00M | $454.00M |
| Accounts Payable | $838.00M | $950.00M | $1.02B | $960.00M | $930.00M | $575.00M |
| Current Assets | $1.61B | $1.62B | $1.83B | $1.73B | $1.83B | $2.02B |
| Total Assets | $5.56B | $5.75B | $5.95B | $6.16B | $6.33B | $6.21B |
| Current Liabilities | $1.92B | $1.57B | $1.92B | $1.78B | $2.06B | $1.42B |
| Long-term Debt | $2.48B | $2.48B | $2.48B | $2.47B | $2.48B | $2.78B |
| Total Liabilities | $5.08B | $5.26B | $5.56B | $5.43B | $5.74B | $5.30B |
| Stockholders' Equity | $321.00M | $328.00M | $220.00M | $556.00M | $411.00M | $908.00M |
| Retained Earnings | $432.00M | $250.00M | $583.00M | $1.05B | $1.04B | $3.57B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $981.00M | $695.00M | $1.16B | $786.00M | $1.28B | $1.55B |
| Investing Cash Flow | ($94.00M) | ($175.00M) | ($223.00M) | ($229.00M) | ($452.00M) | ($252.00M) |
| Financing Cash Flow | ($924.00M) | ($655.00M) | ($753.00M) | ($689.00M) | ($1.39B) | ($523.00M) |
| CapEx | $220.00M | $212.00M | $228.00M | $251.00M | $331.00M | $254.00M |
| Free Cash Flow | $761.00M | $483.00M | $930.00M | $535.00M | $945.00M | $1.29B |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 45.2% | 43.0% | 39.4% | 35.8% | 43.6% | 45.6% |
| Operating margin | 15.2% | 5.6% | 3.2% | 8.5% | 12.3% | 17.6% |
| EBITDA margin | 18.3% | 8.9% | 6.4% | 11.7% | 15.1% | 20.3% |
| Net margin | 11.4% | 3.9% | 2.0% | 6.5% | 9.7% | 14.0% |
| Free cash flow margin | 10.7% | 6.8% | 12.6% | 7.5% | 12.9% | 19.2% |
| FCF / Net income | 0.94 | 1.73 | 6.24 | 1.16 | 1.33 | 1.38 |
| R&D / Revenue | 1.7% | 1.8% | 1.9% | 1.9% | 2.0% | 2.2% |
| SG&A / Revenue | 15.8% | 16.5% | 16.0% | 13.4% | 13.7% | 14.4% |
| Effective tax rate | 23.9% | 27.5% | 34.1% | 22.7% | 20.3% | 20.8% |
| Return on assets | 14.6% | 4.9% | 2.5% | 7.5% | 11.2% | 15.1% |
| Return on equity | 252.3% | 85.4% | 67.7% | 83.1% | 172.7% | 103.4% |
| Return on invested capital | 29.3% | 10.3% | 5.8% | 15.5% | 24.8% | 25.5% |
| Liquidity | ||||||
| Current ratio | 0.84 | 1.03 | 0.95 | 0.97 | 0.89 | 1.42 |
| Quick ratio | 0.57 | 0.63 | 0.59 | 0.54 | 0.52 | 1.10 |
| Cash ratio | 0.09 | 0.13 | 0.19 | 0.10 | 0.16 | 0.61 |
| Leverage | ||||||
| Debt / Equity | 7.74 | 7.56 | 11.26 | 4.45 | 6.04 | 3.06 |
| Debt / Assets | 0.45 | 0.43 | 0.42 | 0.40 | 0.39 | 0.45 |
| Debt / EBITDA | 1.92 | 3.92 | 5.23 | 2.98 | 2.24 | 2.04 |
| Interest coverage | 12.3x | 4.4x | 2.6x | 5.7x | 9.1x | 12.0x |
| Equity multiplier | 17.32 | 17.53 | 27.02 | 11.08 | 15.41 | 6.84 |
| Liabilities / Assets | 0.91 | 0.91 | 0.93 | 0.88 | 0.91 | 0.85 |
| Efficiency | ||||||
| Asset turnover | 1.28 | 1.23 | 1.24 | 1.15 | 1.16 | 1.08 |
| Inventory turnover | 7.44 | 6.35 | 6.44 | 6.04 | 5.51 | 8.06 |
| Days sales outstanding | 42d | 36d | 34d | 35d | 30d | 35d |
| Days inventory outstanding | 49d | 57d | 57d | 60d | 66d | 45d |
| Days payable outstanding | 79d | 86d | 83d | 77d | 82d | 57d |
| Cash conversion cycle | 13d | 8d | 8d | 19d | 14d | 23d |
| Valuation | ||||||
| P / E | 18.4x | 60.7x | 132.5x | 37.8x | 32.2x | 29.8x |
| P / B | 46.5x | 51.9x | 89.8x | 31.4x | 55.7x | 30.8x |
| P / S | 2.1x | 2.4x | 2.7x | 2.5x | 3.1x | 4.2x |
| EV / EBITDA | 13.3x | 30.5x | 46.1x | 23.8x | 22.6x | 21.9x |
| Growth | ||||||
| Revenue growth (YoY) | 0.2% | -4.0% | 4.0% | -3.2% | 9.2% | 8.2% |
| Revenue CAGR (3y) | -0.0% | -1.1% | 3.2% | 4.6% | 10.0% | 4.0% |
| Revenue CAGR (5y) | 1.1% | 2.7% | 6.0% | 3.5% | 5.0% | 3.5% |
| Gross profit growth (YoY) | 5.4% | 4.8% | 14.3% | -20.4% | 4.4% | 12.3% |
| Operating income growth (YoY) | 170.9% | 67.2% | -60.8% | -32.6% | -24.1% | 15.7% |
| Net income growth (YoY) | 189.3% | 87.9% | -67.7% | -34.9% | -24.4% | 14.5% |
| EPS growth (YoY) | 189.8% | 87.5% | -67.8% | -33.2% | -24.2% | 16.5% |
| EPS CAGR (3y) | 20.5% | -26.1% | -45.4% | -16.1% | -3.8% | 11.4% |
| EPS CAGR (5y) | -2.4% | -18.7% | -28.1% | -6.9% | 2.5% | 11.0% |
| FCF growth (YoY) | 57.6% | -48.1% | 73.8% | -43.4% | -26.9% | 64.4% |
| FCF CAGR (5y) | -10.0% | -9.3% | 3.6% | -3.4% | 9.3% | 11.5% |
| Book value growth (YoY) | -2.1% | 49.1% | -60.4% | 35.3% | -54.7% | 62.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-06-30.
Business segments
$7.07B totalHealth And Wellness$2.70B · 38.2%
Household$2.00B · 28.3%
Lifestyle$1.30B · 18.4%
International$1.06B · 15.1%
Geographic
$7.10B totalUS$6.08B · 85.6%
Non Us$1.02B · 14.4%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.93
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
7/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Specialty Cleaning, Polishing and Sanitation Preparations
Comparing CLOROX CO /DE/ against the 4 most active filers in the same SIC group.
Dividends
$4.96/share trailing 12 months · +1.6% YoY
| Ex-date | Per share |
|---|---|
| Apr 22, 2026 | $1.2400 |
| Jan 28, 2026 | $1.2400 |
| Oct 22, 2025 | $1.2400 |
| Aug 13, 2025 | $1.2400 |
| Apr 23, 2025 | $1.2200 |
| Jan 29, 2025 | $1.2200 |
| Oct 23, 2024 | $1.2200 |
| Aug 14, 2024 | $1.2200 |
| Apr 23, 2024 | $1.2000 |
| Jan 23, 2024 | $1.2000 |
| Oct 24, 2023 | $1.2000 |
| Aug 8, 2023 | $1.2000 |
| Apr 25, 2023 | $1.1800 |
| Jan 24, 2023 | $1.1800 |
| Oct 25, 2022 | $1.1800 |
| Jul 26, 2022 | $1.1800 |
| Apr 26, 2022 | $1.1600 |
| Jan 25, 2022 | $1.1600 |
| Oct 26, 2021 | $1.1600 |
| Jul 27, 2021 | $1.1600 |
| Apr 20, 2021 | $1.1100 |
| Jan 26, 2021 | $1.1100 |
| Nov 3, 2020 | $1.1100 |
| Jul 28, 2020 | $1.1100 |